Douglas W Blayney1,2, Melora K Simon2, Beatrice Podtschaske2,3, Scott Ramsey4, Margaret Shyu2,5, Craig Lindquist2, Arnold Milstein2. 1. Stanford Cancer Institute, Stanford, California. 2. Clinical Excellence Research Center, Stanford University, Stanford, California. 3. Now with Stanford Healthcare, Stanford, California. 4. Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, Washington. 5. Now with Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Abstract
IMPORTANCE: Cancer care is expensive. Cancer care provided by practice organizations varies in total spending incurred by patients and payers during treatment episodes and in quality of care, and this unnecessary variation contributes to the high cost. OBJECTIVE: To use the variation in total spending and quality of care to assess oncology practice attributes distinguishing "high value" that may be tested and adopted by others to produce similar results. DESIGN, SETTING, AND PARTICIPANTS: "Positive deviance" was used in this exploratory mixed-methods (quantitative and qualitative) analysis of interview results. To quantify value, oncology practices located near the US Pacific Northwest and Midwest with low mean insurer-allowed spending were identified. Among those, practices with high quality were selected. A team then conducted site visits to interview practice personnel from June 2, 2015, through October 3, 2015, and to probe for attributes of high-value care. A qualitative analysis of their interview results was performed, and a panel of experienced oncologists was convened to review attributes occurring uniquely or frequently in low-spending practices for their contribution to value improvement and ease of implementation. Four positive deviant (ie, low-spending) oncology practices and 3 oncology practices that ranked near the middle of the spending distribution were studied. MAIN OUTCOMES AND MEASURES: Thematic saturation in a qualitative analysis of high-value care attributes. RESULTS: From the 7 oncology practices studied, 13 attributes within the following 5 themes emerged: treatment planning and goal setting, services supporting the patient journey, technical support and physical layout, care team organization and function, and external context. Five attributes (ie, conservative use of imaging, early discussion of treatment limitations and consequences, single point of contact, maximal use of registered nurses for interventions, and a multicomponent health care system) most sharply distinguished the high-value practice sites. The expert oncologist panel judged 3 attributes (ie, early and normalized palliative care, ambulatory rapid response, and early discussion of treatment limitations and consequences) to carry the highest immediate potential for lowering spending without compromising the quality of care. CONCLUSIONS AND RELEVANCE: Oncology practice attributes warranting further testing were identified that may lower total spending for high-quality oncology care.
IMPORTANCE: Cancer care is expensive. Cancer care provided by practice organizations varies in total spending incurred by patients and payers during treatment episodes and in quality of care, and this unnecessary variation contributes to the high cost. OBJECTIVE: To use the variation in total spending and quality of care to assess oncology practice attributes distinguishing "high value" that may be tested and adopted by others to produce similar results. DESIGN, SETTING, AND PARTICIPANTS: "Positive deviance" was used in this exploratory mixed-methods (quantitative and qualitative) analysis of interview results. To quantify value, oncology practices located near the US Pacific Northwest and Midwest with low mean insurer-allowed spending were identified. Among those, practices with high quality were selected. A team then conducted site visits to interview practice personnel from June 2, 2015, through October 3, 2015, and to probe for attributes of high-value care. A qualitative analysis of their interview results was performed, and a panel of experienced oncologists was convened to review attributes occurring uniquely or frequently in low-spending practices for their contribution to value improvement and ease of implementation. Four positive deviant (ie, low-spending) oncology practices and 3 oncology practices that ranked near the middle of the spending distribution were studied. MAIN OUTCOMES AND MEASURES: Thematic saturation in a qualitative analysis of high-value care attributes. RESULTS: From the 7 oncology practices studied, 13 attributes within the following 5 themes emerged: treatment planning and goal setting, services supporting the patient journey, technical support and physical layout, care team organization and function, and external context. Five attributes (ie, conservative use of imaging, early discussion of treatment limitations and consequences, single point of contact, maximal use of registered nurses for interventions, and a multicomponent health care system) most sharply distinguished the high-value practice sites. The expert oncologist panel judged 3 attributes (ie, early and normalized palliative care, ambulatory rapid response, and early discussion of treatment limitations and consequences) to carry the highest immediate potential for lowering spending without compromising the quality of care. CONCLUSIONS AND RELEVANCE: Oncology practice attributes warranting further testing were identified that may lower total spending for high-quality oncology care.
Authors: Christine A Sinsky; Rachel Willard-Grace; Andrew M Schutzbank; Thomas A Sinsky; David Margolius; Thomas Bodenheimer Journal: Ann Fam Med Date: 2013 May-Jun Impact factor: 5.166
Authors: Douglas W Blayney; Kristen McNiff; Peter D Eisenberg; Terry Gilmore; Paul B Jacobsen; Joseph O Jacobson; Pamela J Kadlubek; Michael N Neuss; Joseph Simone Journal: J Clin Oncol Date: 2014-09-15 Impact factor: 44.544
Authors: Michael N Neuss; Christopher E Desch; Kristen K McNiff; Peter D Eisenberg; Dean H Gesme; Joseph O Jacobson; Mohammad Jahanzeb; Jennifer J Padberg; John M Rainey; Jeff J Guo; Joseph V Simone Journal: J Clin Oncol Date: 2005-08-08 Impact factor: 44.544
Authors: Brian M Brady; Meera V Ragavan; Melora Simon; Glenn M Chertow; Arnold Milstein Journal: J Am Soc Nephrol Date: 2019-11-14 Impact factor: 10.121
Authors: Isaac S Chua; Michal Gaziel-Yablowitz; Zfania T Korach; Kenneth L Kehl; Nathan A Levitan; Yull E Arriaga; Gretchen P Jackson; David W Bates; Michael Hassett Journal: Cancer Med Date: 2021-05-07 Impact factor: 4.452
Authors: Stephanie Deeb; Fumiko L Chino; Lisa C Diamond; Anna Tao; Abraham Aragones; Armin Shahrokni; Divya Yerramilli; Erin F Gillespie; C Jillian Tsai Journal: JAMA Netw Open Date: 2021-09-01
Authors: Alex Fauer; Sung Won Choi; Lauren P Wallner; Matthew A Davis; Christopher R Friese Journal: Cancer Causes Control Date: 2021-02-10 Impact factor: 2.506